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Purpose: Vogt-Koyanagi-Harada (VKH) disease and sympathetic ophthalmia (SO) are two distinct entities that share
common clinical and histopathological features; however, it remains unknown whether they have a common genetic
susceptibility. Several studies have shown an association of human leukocyte antigen (HLA)-DR4 with VKH disease in
patients of different ethnic backgrounds. We present in this paper the HLA-DRB1 genotyping analysis of a large cohort
of VKH patients from southern India and compare these patients to patients with SO and to healthy individuals from the
same geographic area.
Methods: VKH patients were diagnosed according to the revised criteria of the International Committee on VKH disease.
Patients with granulomatous uveitis after ocular trauma or multiple eye surgeries were diagnosed as having SO. Genomic
DNA was extracted from all patients and controls. Samples were analyzed for HLA-DRB1 alleles by reverse polymerase
chain  reaction  (PCR)  sequence-specific  oligonucleotide  (SSO)  hybridization  on  microbeads,  using  the  Luminex
technology,  and  by  PCR  sequence-specific  primers  (SSP)  typing  for  DRB1*04  allele  determination.  Strength  of
associations was estimated by odds ratios (OR) and 95% confidence intervals (CI) and frequencies were compared using
the Fisher’s exact test.
Results: HLA-DRB1 alleles were determined in 94 VKH patients, 39 SO patients, and 112 healthy controls. HLA-
DRB1*04 frequency was higher in VKH patients (20.2% versus 10.3% in controls; OR=2.2, p=0.005, pc=0.067). This
association was lower than the association of HLA-DRB1*04 frequency in cohorts of patients from different origins. No
significant DR4 association with SO was detected. HLA-DRB1*0405 and HLA-DRB1*0410 alleles were significantly
increased in VKH patients (8.5% versus 0.9% in controls; OR=10.3, 95% CI=2.34–45.5, p<0.001). These two alleles
share the epitope S57-LLEQRRAA (67–74) in the third hypervariable region of the HLA-DR molecule. None of the DRB1
alleles was significantly associated with SO.
Conclusions: Based on the association of HLA-DRB1*0405 and HLA-DRB1*0410 alleles with VKH disease, we propose
that the epitope S57-LLEQRRAA (67–74) in the third hypervariable region of the HLA-DRβ1 molecule is the relevant
susceptibility epitope. This genetic component seems specific to VKH disease since no correlation could be identified in
SO patients. The weaker association with HLA-DR4 in this VKH patient cohort compared to VKH patients from northern
India is probably related to the lower frequency of HLA-DRB1*0405 in our study group. The HLA-DRB1 association with
susceptibility to VKH syndrome seems weaker in Indian patients compared to Japanese or Hispanic patients, suggesting
a different non-HLA immunogenetic background in Indian VKH patients.
Vogt-Koyanagi-Harada  (VKH)  disease  is  a  serious
ocular inflammatory syndrome characterized by the presence
of  bilateral  panuveitis  and  exudative  retinal  detachments.
Alopecia, vitiligo, poliosis, tinnitus, and meningeal symptoms
may also be present according to the stage of the disease.
Several criteria are needed to establish the diagnosis of VKH
(e.g., bilateral uveitis, meningismus, and extra-ocular signs).
The  absence  of  a  history  of  trauma/surgery  is  essential.
Correspondence  to:  Dr.  Edoardo  Baglivo,  Clinique
d’Ophtalmologie, Hôpitaux Universitaires de Genève, Rue Alcide-
Jentzer, 22 CH-1205, Genève, Switzerland; Phone: +4122 382 8436;
FAX: +4122 382 8382; email: edoardo.baglivo@hcuge.ch
Recently, revised diagnostic criteria were proposed by the
First VKH International Workshop group, which classified
the disease as complete, incomplete, and probable according
to  the  presence  of  clinical  signs  [1].  Some  studies  have
suggested that VKH is a T-lymphocyte-mediated disease and
that specific auto-antigens may play a role in its pathogenesis
[2,3].
Although VKH and sympathetic ophthalmia (SO) are two
distinct entities, they share common clinical features (bilateral
granulomatous  uveitis)  and  histopathological  signs
(infiltration of T-lymphocytes in the choroid and preservation
of the choriocapillaris and retina) [4].
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353Genetic  specificities  of  the  human  leucocyte  antigen
(HLA) system have been associated with susceptibility to
many  autoimmune  diseases.  The  initial  discovery  of  the
human leukocyte antigen (HLA)-DR4 association with VKH
disease in Japanese patients [5] has been confirmed in several
subsequent studies including Chinese [6], North American
[7], Korean [3], Japanese [8,9], Italian [10], Hispanic [11],
Mestizos [12,13], and strongly admixed Brazilian patients
[14]. In several reports, the higher frequency of DR4 in VKH
patients was related to the HLA-DRB1*0405 allele, and in
three  Japanese  studies  a  significant  increase  in  HLA-
DRB1*0410  was  observed  [8,15,16].  In  Mestizo  patients,
gene  frequencies  for  HLA-DRB1*0102,  HLA-DRB1*0404,
HLA-DRB1*0407, and HLA-DRB1*0410 alleles were higher
than in controls [13]. A recent study on 30 patients from Saudi
Arabia reported a significant association of VKH with HLA-
DRB1*0405 [17].
In the present article, we examined the frequency of HLA-
DRB1 alleles in a large cohort of VKH patients from southern
India and compared this with patients with SO and healthy
individuals from the same geographic area.
METHODS
Study samples: We prospectively included 94 VKH patients,
39 SO patients, and 112 healthy subjects. All patients with
VKH and SO were examined at the Uveitis Clinic of the
Aravind Eye Hospital, Madurai, India.
Patients  were  diagnosed  with  VKH  according  to  the
revised  criteria  of  the  International  Committee  on  VKH
disease [1]. In the absence of a history of trauma/surgery and
after exclusion of other uveitis causes, patients presenting
with bilateral uveitis with exudative retinal detachment and a
history of meningismus, CSF pleocytosis, or sensorineural
deafness  with  integumentary  changes  were  diagnosed  as
having complete VKH. Incomplete VKH was diagnosed in
the presence of either signs or symptoms of central nervous
system (CNS) involvement or integumentary changes. In the
absence of both CNS and integumentary changes, patients
were diagnosed as having probable VKH syndrome.
Patients  presenting  with  granulomatous  uveitis  after
ocular trauma or multiple eye surgeries were diagnosed with
SO. For each patient other causes of granulomatous uveitis
were excluded by an extensive work-up.
All patients had a complete eye examination, including
Snellen visual acuity, slit-lamp biomicroscopy, tonometry,
and  dilated  fundus  examination.  Intraocular  inflammation
was  graded  according  to  the  International  Uveitis  Study
Group recommendations [18]. Demographic data included
gender, present age, and age at onset of VKH or SO. The
present study was approved by the local Ethics Committee,
and  written  informed  consent  was  obtained  from  all
participants.
Analytical methods: For each subject a blood sample was
taken and genomic DNA was extracted. All samples were
analyzed for HLA-DRB1 alleles by reverse polymerase chain
reaction  (PCR)  sequence-specific  oligonucleotide  (SSO)
reverse  hybridization  on  microbead  arrays  (Luminex
technology; Luminex Corporation, Austin, TX) after locus-
specific  amplification  on  genomic  DNA  samples,  using
LabType  RSSO2B  reagents  (OneLambda,  Ingen,  Chilly
Mazarin,  France).  This  assay  provided  results  at  an
intermediate level (groups of alleles), with assignment of the
four-digit allele in some cases. The HLA-DRB1*04-positive
samples were subtyped by PCR sequence-specific primers
(PCR-SSP;  Genovision,  Milan  Analytika  AG,  Magden,
Switzerland).  Intermediate  resolution  level  data  were
expressed as HLA-DRB1 two-digit types.
Statistical analysis: Group comparison proceeded with the
Fisher’s exact test for gender and disease severity and the
Kruskal–Wallis test for age. Comparison of allele frequencies
was performed with the Fisher’s exact test. The strength of the
associations  was  estimated  by  odds  ratios  (OR)  and  95%
confidence  intervals  (CI).  Haldane’s  correction  was  used
when a value was zero in a 2×2 table. The threshold for
statistical significance was set at p=0.05, and all tests were
two-sided. P-values were corrected according to Bonferroni
(pc,  corrected  p-value)  when  multiple  comparisons  were
made.  Statistical  analysis  was  performed  with  the  SPSS
software, version 17 (SPSS Inc., Chicago, IL).
RESULTS
As indicated in Table 1, 245 subjects were recruited, including
94 VKH patients (median age 40 years; 73.4% female), 39 SO
TABLE 1. PATIENT CHARACTERISTICS.
 Variable   Value
VKH patients (n=94) SO patients (n=39) Control subjects (n=112)
p-value*
Gender male (number, %) 25 26.6 22 56.4 70 62.5 <0.001
  female (number, %) 69 73.4 17 43.6 42 37.5  
Age (years) (median, range) 40 7–86 45 14–73 56 14–79 <0.001
Severity of illness# moderate (number, %) 20 22.5 14 40.0     0.072
  severe (number, %) 69 77.5 21 60.0      
The asterisk indicates Fisher's exact test for proportions; Kruskal–Wallis test for age. The sharp (hash mark) indicates missing
values (n=5 in VKH; n=4 in SO).
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†patients  (median  age  45  years;  43.6%  female;)  and  112
healthy controls (median age 56 years; 37.5% female;). All
patients and controls were Indian Tamils.
We  first  compared  the  HLA-DRB1  intermediate
resolution typing results among the three study groups. When
considering two-digit allele type frequencies (Table 2), HLA-
DRB1*04 displayed a frequency about twofold higher in VKH
patients  than  in  controls  (20.2%  versus  10.3%,  OR=2.2,
p=0.005,  pc=0.067).  All  other  differences  between  VKH
patients and controls were nonsignificant, including the lower
frequency of HLA-DRB1*15 in VKH patients (19.1% versus
26.3%, OR=0.66, p=0.10). Comparisons between SO patients
and controls did not reveal any significant association.
Similar results were obtained when genotype frequencies
were  considered  (data  not  shown).  HLA-DRB1*04  was
present in 37.2% of VKH patients, 25.6% of SO patients, and
19.6% of controls, with a significant difference between VKH
patients and controls (OR=2.4, p=0.008, pc=0.094).
We then considered high-resolution typing for DR1 and
DR4 alleles (Table 3). Results showed a significantly higher
frequency of HLA-DRB1*0405/HLA-DRB1*0410 alleles in
VKH patients than in controls (8.5% versus 0.9%, OR=10.3,
p<0.001). As illustrated in Figure 1, the HLA-DRB1*0405 and
HLA-DRB1*0410 alleles share the S57-LLEQRRAA (67–74)
epitope in the α-1 domain of the DR β-chain. VKH patients
also showed a slightly, but nonsignificantly, higher frequency
of  HLA-DRB1*0101  and  HLA-DRB1*0403/HLA-
DRB1*0407  alleles,  which  share  the  LLEQRRA  (67–73)
epitope  with  HLA-DRB1*0405/HLA-DRB1*0410,  while
HLA-DRB1*0403/HLA-DRB1*0407 differ at residue 74 (Ala
versus Glu). HLA-DRB1*0405/HLA-DRB1*0410 showed no
significant association with SO disease.
Results were similar when genotype frequencies were
considered  (data  not  shown).  HLA-DRB1*0405/HLA-
DRB1*0410 was present in 17.0% of VKH patients, 7.7% of
SO  patients,  and  1.8%  of  controls,  with  a  significant
difference between VKH patients and controls (OR=11.3,
p<0.001).
Disease severity could be assigned for 89 VKH patients.
The frequency of HLA-DRB1*0405/HLA-DRB1*0410 alleles
was slightly higher in more severe disease conditions, but the
difference was not significant (9.4% versus 7.5%, p=1).
DISCUSSION
In the present study, we found a significantly higher frequency
of the HLA-DRB1*0405/HLA-DRB1*0410 alleles in a cohort
of 94 VKH patients from southern India compared to healthy
controls  (Table  3).  We  propose  that  the  epitope  S57-
LLEQRRAA (67–74) in the third hypervariable region of the
DR β-1-chain (Figure 1) could be relevant to the susceptibility
to VKH syndrome. In this cohort, residue S57 alone could not
account for the susceptibility, as proposed previously [8],
since S57-positive HLA-DRB1*08 allele frequency did not
significantly differ between VKH patients and controls (Table
2).
Alternatively, if the weak association of VKH disease
with  HLA-DRB1*0101  and  HLA-DRB1*0403/HLA-
DRB1*0407  is  considered  as  relevant,  the  susceptibility
epitope shared by the five alleles would be LLEQRRA (67–
73)  in  the  third  hypervariable  region  of  DRβ1  molecules
(Table  3,  Figure  1).  This  epitope  exhibits  considerable
similarity to the rheumatoid arthritis-shared epitope [19]. The
observed  association  of  VKH  with  DR1  in  some  patient
cohorts [13] would support this possibility, although HLA-
DRB1*0403/HLA-DRB1*0407 were not increased among 48
Japanese VKH patients [15].
Because  the  association  between  VKH  and  HLA-
DRB1*0405/HLA-DRB1*0410 was much stronger than with
HLA-DRB1*0101/HLA-DRB1*0403/HLA-DRB1*0405/
HLA-DRB1*0407/HLA-DRB1*0410 (OR 10.3 versus 2.4) in
the  present  study,  our  data  favor  the  hypothesis  of  a
susceptibility epitope shared by HLA-DRB1*0405 and HLA-
DRB1*0410 alleles in south Indian patients. The nonpolar
alanine at residue 74 of HLA-DRB1*0405/HLA-DRB1*0410
could  be  crucial  in  increasing  the  affinity  of  antigenic
Figure 1. The third hypervariable region sequence of the human
leukocyte antigen (HLA)-DRB1 first domain of the alleles identified
in patients and controls. Residues 51–80 are represented. In addition
to the alleles included in the figure, the following rare alleles were
also observed in this study: HLA-DRB1*0305, HLA-DRB1*0407,
HLA-DRB1*0804,  HLA-DRB1*1106,  HLA-DRB1*1111,  HLA-
DRB1*1415,  HLA-DRB1*1506,  HLA-DRB1*1507,  HLA-
DRB1*1509, HLA-DRB1*1514, and HLA-DRB1*1602. Amino acid
sequences are shown using the one-letter code. The epitope S57–
LLEQRRAA (67–74) is highlighted.
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356peptide(s) to the HLA-DR4 molecule and/or T cell receptor
recognition. A role of Ser at position 57, predicted to point
toward the peptide-binding cleft, should also be considered.
In a cohort of 57 Japanese patients, the association of
HLA-DRB1*0405/HLA-DRB1*0410  was  stronger  with
prolonged than nonprolonged VKH disease [16]. Our results
similarly  showed  a  slightly  higher  frequency  of  HLA-
DRB1*0405/HLA-DRB1*0410  in  patients  with  severe
compared to moderate disease conditions, but the difference
was not statistically significant. A role of DQB1*0402, which
is  in  linkage  disequilibrium  with  HLA-DRB1*0405/HLA-
DRB1*0410, seems unlikely because 40% of 15 tested VKH
patients were DQB1*0402 negative (data not shown).
The HLA-DR susceptibility epitope could slightly differ
in  populations  with  different  genetic  backgrounds.
Accordingly, south Indian VKH patients in the present study
might be closer to other Asian cohorts than to Hispanics.
However, in a recent study of North Indian VKH patients, no
association with DR4 was observed, which is possibly related
to the high prevalence of patients with incomplete syndrome
and  to  the  low  frequency  of  HLA-DRB1*0405  in  this
population  [20,21].  When  compared  with  a  north  Indian
population [20], the present south Indian control population
was characterized by a twofold higher relative frequency of
HLA-DRB1*0403 (69.6% versus 34.8% in the north Indian
population), whereas frequencies of HLA-DRB1*0405 and
HLA-DRB1*0410  were  lower  (4.3%  versus  11.2%)  and
comparable (4.3% versus 3.4%), respectively.
Even  though  the  present  results  reveal  a  strong
association  of  VKH  with  the  HLA-DRB1*0405/HLA-
DRB1*0410 alleles, the frequency of these two alleles was
relatively low in this south Indian population. In conclusion,
although highly significant, the immunogenetic basis of HLA-
DRB1  associations  with  susceptibility  to  VKH  syndrome
seems to be weaker in south Indian Tamils than in Japanese
or  Hispanic  patients.  Additional  genetic  systems,  such  as
killer immunoglobulin-like receptor–HLA interactions could
also play a role, as suggested recently in a small cohort of
Mestizo  VKH  patients  [22].  Finally,  no  HLA-DRB1
association could be observed with SO, which is in accordance
with the clearly different physiopathology of both diseases.
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